10.05.2017 – 07:37

LifeWatch AG

EQS-Adhoc: LifeWatch AG: Hauptangebotsfrist vom Übernahmeangebot von BioTelemetry, Inc. für LifeWatch AG beginnt

EQS Group-Ad-hoc: LifeWatch AG / Schlagwort(e): Übernahmeangebot
LifeWatch AG: Hauptangebotsfrist vom Übernahmeangebot von BioTelemetry, Inc. für
LifeWatch AG beginnt

10.05.2017 / 07:00 CET/CEST
Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR
--------------------------------------------------------------------------------
Hauptangebotsfrist vom Übernahmeangebot von BioTelemetry, Inc. für LifeWatch AG
beginnt

Zug/Schweiz, 10. Mai 2017 - LifeWatch AG (SIX: LIFE), ein führender Anbieter von
ferngesteuerten diagnostischen "Digital Health" Dienstleistungen, gibt heute den
Beginn der Hauptangebotsfrist für das Übernahmeangebot durch BioTelemetry, Inc.
(NASDAQ: BEAT) bekannt, welche zehn (10) Handelstage dauert und am 23. Mai 2017
um 16:00 Uhr MEZ endet. Der Vollzug erfolgt unter Vorbehalt der
wettbewerbsrechtlichen und anderen üblichen Angebotsbedingungen. Wie zuvor im
Bericht des Verwaltungsrats von LifeWatch dargelegt, unterstützt dieser das
öffentliche Übernahmeangebot von BioTelemetry und empfiehlt den Aktionären
dessen Annahme.

Das Angebot von BioTelemetry bietet den Aktionären von LifeWatch, die ihre
Aktien veräussern, zwei Möglichkeiten: Sie erhalten entweder CHF 10.00 in bar
und 0.1457 Aktien von BioTelemetry (Hauptangebot) (entspricht CHF 4.00 pro
LifeWatch-Aktie, basierend auf dem Schlusskurs von BioTelemetry am Freitag, 7.
April 2017) oder CHF 8.00 in bar und 0.2185 Aktien von BioTelemetry
(Alternativangebot) (entspricht CHF 6.00 pro LifeWatch-Aktie, basierend auf dem
Schlusskurs von BioTelemetry am Freitag, 7. April 2017), je nach individueller
Präferenz des Aktionärs.

Unter Berücksichtigung des Schlusskurses der BioTelemetry-Aktie vom 9. Mai 2017
entspricht das Angebot einem Gegenwert von CHF 14.34 (Hauptangebot)
beziehungsweise CHF 14.51 (Alternativangebot) pro LifeWatch-Aktie. Durch den
Anstieg des Aktienpreises von BioTelemetry seit der ursprünglichen Ankündigung
am 9. April 2017 ist der Gesamtwert der Übernahme von CHF 259 Millionen (per 7.
April 2017) auf einen Wert von CHF 265 Millionen bis CHF 268 Millionen
gestiegen.

Weitere Informationen finden sich im Bericht des Verwaltungsrats von LifeWatch
sowie der von der Raiffeisen erstellten Fairness Opinion unterhttps://lifewatch.
com/Investor-Relations/Public-Tender-Offer-Cardiac-Monitoring.html, im
Angebotsprospekt von BioTelemetry unterhttps://www.gobio.com/ sowie auf der
Website des Swiss Takeover Boardswww.takeover.ch.


Für Rückfragen:
LifeWatch AG, Andrew Moore, CFO
c/o Communicators AG , Ralph Spillmann
Mobile: +41 79 514 64 84
E-Mail:investor-relations@lifewatch.com


Zu LifeWatch AG
LifeWatch AG, mit Hauptsitz in Zug und Kotierung an der SIX Swiss Exchange
(LIFE) in der Schweiz, ist ein führender Anbieter von ferngesteuerten
diagnostischen "Digital Health" Dienstleistungen. Die Dienstleistungen von
LifeWatch liefern den Ärzten wichtige Informationen zur angemessenen Behandlung
ihrer Patienten mit dem Ziel, die Behandlung zu optimieren. LifeWatch AG verfügt
über operative Tochtergesellschaften in den USA, der Schweiz, Israel und der
Türkei und ist die Muttergesellschaft von LifeWatch Services, Inc., LifeWatch
Technologies Ltd. und LifeWatch Turkey Holding AG (Joint Venture). LifeWatch
Services, Inc. ist ein führender US-Anbieter für
Herzüberwachungsdienstleistungen. LifeWatch Technologies Ltd. in Israel ist ein
führender Hersteller von Digital-Health-Produkten. LifeWatch Sağlık Hizmetlerine
A.S. ist die operative Tochtergesellschaft der LifeWatch Turkey Holding AG und
Anbieter von Herzüberwachungsdienstleistungen in der Türkei.

Für weitere Informationen: siehewww.lifewatch.com.

E-Mail Alert:Um regelmässig die neusten Informationen zu LifeWatch zu erhalten
und Unterlagen anzufordern, registrieren Sie sich bitte
unterhttps://www.lifewatch.com/Investor-Relations/Alert-Service.html.

Zu BioTelemetry
BioTelemetry, Inc., früher als CardioNet bekannt, ist ein führendes Unternehmen
im Bereich kabelloser Medizinaltechnologie. Der Fokus liegt auf der
Bereitstellung von Gesundheitsdaten zur Verbesserung der Lebensqualität sowie
zur Reduktion der Gesundheitskosten. Das Unternehmen bietet zurzeit
Herzüberwachungs-Dienstleistungen an und produziert Geräte mit einem primären
Fokus auf die Herzüberwachung sowie zentralisierte Dienstleistungen für
Herzlaboratorien.

Für weitere Informationen: siehewww.biotelinc.com.

Cautionary Statement Regarding Forward-Looking Statements
This document includes certain forward-looking statements regarding, among other
things, statements about both, LifeWatch's and BioTelemetry's beliefs and
expectations, statements about BioTelemetry's proposed acquisition of LifeWatch
AG, including the timing and success of the tender offer and expectations
regarding the growth and success of the combined entity. These statements may be
identified by words such as "expect," "anticipate," "estimate," "intend,"
"plan," "believe," "promises", "projects," and other words and terms of similar
meaning. Such forward-looking statements are based on current expectations and
involve inherent risks and uncertainties, including important factors that could
delay, divert, or change any of these expectations, and could cause actual
outcomes and results to differ materially from current expectations. Factors
that may materially affect such forward-looking statements include:
BioTelemetry's ability to successfully complete the tender offer for LifeWatch's
shares or realize the anticipated benefits of the transaction; and the failure
of any of the conditions to BioTelemetry's tender offer to be satisfied. For
further details and a discussion of these and other risks and uncertainties,
please see BioTelemetry's public filings with the Securities and Exchange
Commission, including the company's latest periodic reports on Form 10-K and
10-Q respectively LifeWatch's past press releases, reports and other information
posted on LifeWatch's website. Readers are cautioned not to put undue reliance
on forward-looking statements, which reflect only opinions as of the date of
this press release. BioTelemetry and LifeWatch do not undertake, and
specifically disclaim, any obligation to publicly update or amend any
forward-looking statement, whether as a result of new information, future
events, or otherwise.

OFFER RESTRICTIONS
The public tender offer described in the offer documents (the "Offer") is not
being and will not be made, directly or indirectly, in any country or
jurisdiction in which it would be considered unlawful or otherwise violate any
applicable laws or regulations, or which would require BioTelemetry or any of
its subsidiaries to change or amend the terms or conditions of the Offer in any
material way, to make an additional filing with any governmental, regulatory or
other authority or take additional action in relation to the Offer. It is not
intended to extend the Offer to any such country or jurisdiction. Any such
documents relating to the Offer must neither be distributed in any such country
or jurisdiction nor be sent into such country or jurisdiction, and must not be
used for the purpose of soliciting the purchase of securities of LifeWatch by
any person or entity resident or incorporated in any such country or
jurisdiction.

Notice to U.S. Persons Holding LifeWatch Shares
The Offer is made for the securities of a non-U.S. company. The Offer is subject
to the disclosure and procedural requirements of Switzerland, which are
different from those of the United States (the "U.S.").

According to the laws of Switzerland, LifeWatch shares tendered into the Offer
may be withdrawn after they are tendered until the expiration of the main offer
period.

BioTelemetry and any of its subsidiaries and any advisor, broker or financial
institution acting as an agent or for the account or benefit of BioTelemetry or
the Offeror may, subject to applicable Swiss securities laws, rules and
regulations, make certain purchases of, or arrangements to purchase, LifeWatch
shares from shareholders of LifeWatch who are willing to sell their LifeWatch
shares outside the Offer from time to time, including purchases in the open
market at prevailing prices or in private transactions at negotiated prices. The
Offeror will disclose promptly any information regarding such purchases of
LifeWatch shares in Switzerland through the electronic media and/or the stock
exchange and in the U.S. by means of a press release, if and to the extent
required under applicable laws, rules and regulations in Switzerland.

It may be difficult for U.S. holders to enforce their rights and any claim
arising out of U.S. federal securities laws, since LifeWatch is located in a
non-U.S. jurisdiction, and some or all of its officers and directors may be
residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a
non-U.S. company or its officers or directors in a non-U.S. court for violations
of the U.S. securities laws. Further, it may be difficult to compel a non-U.S.
company and its affiliates to subject themselves to a U.S. court's judgment.

The receipt of cash and stock consideration in the Offer by a U.S. shareholder
will generally be a taxable transaction for U.S. federal, state and local income
tax purposes. Each U.S. shareholder is urged to consult his independent
professional adviser immediately regarding the tax consequences of acceptance of
the Offer.

Securities may not be offered or sold in the U.S. absent registration or an
exemption from registration under the U.S. Securities Act. It is expected that
the Offer will be subject to a Tier I exemption pursuant to Rule 14d-1(c) of the
U.S. Securities Exchange Act of 1934, as amended, and that the issuance of
BioTelemetry Common Stock in connection therewith will be exempt from
registration under the U.S. Securities Act of 1933, as amended, pursuant to Rule
802 thereof.

Neither the Securities and Exchange Commission nor any securities commission of
any State of the U.S. has (a) approved or disapproved of the Offer, (b) passed
upon the merits or fairness of the Offer, or (c) passed upon the adequacy or
accuracy of the disclosure in the pre-announcement. Any representation to the
contrary is a criminal offense in the U.S.

Im Zweifelsfall gilt die englische Originalmeldung.

Zusatzmaterial zur Meldung:


Dokument:http://n.eqs.com/c/fncls.ssp?u=DJOBMMJWLF
Dokumenttitel: 20170510_Start Main Offer Period_DE
--------------------------------------------------------------------------------
Ende der Ad-hoc-Mitteilung------------------------------------------------------

Sprache:       Deutsch

Unternehmen:   LifeWatch AG

               Baarerstrasse 139

               6300 Zug

               Schweiz

Telefon:       +41 41 728 67 78

Internet:   www.lifewatch.com

ISIN:          CH0012815459

Valorennummer: 811189

Börsen:        Freiverkehr in Berlin, Stuttgart; Open Market in Frankfurt; SIX
Swiss Exchange



 

Ende der Mitteilung EQS Group News-Service

--------------------------------------------------------------------------------

571635  10.05.2017 CET/CEST